Anders Rehfeld
Development of an unisex contraceptive through inhibition of the human sperm CatSper Ca(2+)-channel
CLINICAL POSTDOC
Anders Rehfeld, MD, Juliane Marie Centre, Rigshospitalet, has been awarded a postdoc research grant from Lundbeck Foundation worth DKK 2,500,000.
His project seeks to develop a whole new type of contraceptive that can be used by men and women – and that does not involve hormones, as is the case with, e.g., contraceptive pills. The aim is to utilise characteristics from a small pharmaceutical molecule which has proven particularly effective at blocking a key ion channel in sperm cells. This channel must be active in order for the cells to move towards an egg that is ready to be fertilised.
Taking this pharmaceutical molecule as his point of departure, Anders Rehfeld will now produce various substances for preliminary mouse studies.
